Comments
Aragen Life Sciences (formerly GVK BIO) has announced that it has been selected by Skyhawk Therapeutics, a leader in the development of small molecule therapeutics that correct RNA expression, as its partner in India.
Through this collaboration, Aragen, a Contract Research and Development Organization (CRDO) headquartered in Hyderabad, will provide Skyhawk with various discovery chemistry and biology service solutions.
This partnership is focussed on accelerating Skyhawk’s research pipeline.
Also read: Aragen Life expands discovery research pact with Boehringer Ingelheim
“At Aragen, we believe that in every molecule is the possibility for better health. It is with this spirit that we look forward to leveraging Aragen’s 20 years of discovery research expertise to help Skyhawk advance the development of its novel small molecule therapeutics targeting some of the world’s most intractable diseases,” said Manni Kantipudi, CEO, Aragen.
Aragen Life Sciences with a team of over 3,100 professionals, and through a network of sites around the world, offers integrated platform to advance customer programmes from discovery through commercialisation for both small molecules and biologics.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.